| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02907307 Details | 2019-03-08 Interventional | 3 | 0 | Clotrimazole Miconazole Candidiasis Candidiasis, Vu… Vulvovaginal Ca… | Development project stopped - | |||
| NCT03695822 Details | 2019-03-07 Interventional | 4 | 0 | Mirabegron Syndrome Urinary Bladder… Overactive Blad… | I did not pass the 2018 Ministry of Science and Technology research project subsidy, so I
applied for the project to close the case. - | |||
| NCT03060980 Details | 2019-03-07 Interventional | 3 | 245 | Empagliflozin Exenatide Glimepiride Diabetes Mellit… | Decision by Sponsor - | |||
| NCT02857465 Details | 2019-03-07 Interventional | 3 | 0 | BB 1101 Dexamethasone Dexamethasone a… Dsuvia Ropivacaine Sufentanil Labor Pain Obstetric Pain Other Complicat… | French Agency for the Safety of Health Products refusal - | |||
| NCT01785771 Details | 2019-03-07 Interventional | 3 | - | Exenatide Diabetes Mellit… Diabetes Mellit… Type 2 Diabetes | Decision by Sponsor - | |||
| NCT01587261 Details | 2019-03-06 Interventional | 2 | 0 | Ascorbic Acid Burns Wounds and Inju… Severe Thermal … | This potential study was held up at the level of the FDA as they wouldn't approve and IND for
the dose of vitamin C we wanted to use. - | |||
| NCT01198158 Details | 2019-03-06 Interventional | 3 | 77 | Antibodies Antibodies, Mon… Antineoplastic … Bevacizumab Endothelial Gro… Everolimus Immunoglobulin … Immunoglobulins Carcinoma Carcinoma, Rena… Clear Cell Rena… Recurrent Renal… Stage III Renal… Stage IV Renal … | - - | |||
| NCT00754923 Details | 2019-03-06 Interventional | 2 | 11 | Sorafenib Carcinoma, Non-… Lung Neoplasms Lung Cancer | - The study was discontinued, after withdrawal from the sponsor due to slow accrual. The discovery of EGFR mutations changed the scope of the trial. | |||
| NCT00365937 Details | 2019-03-06 Interventional | 1/2 | 19 | Adjuvants, Immu… Monatide (IMS 3… Melanoma | New regulatories of the peptides by the pharmaceutical company (the seller) - | |||
| NCT03172988 Details | 2019-03-05 Interventional | 4 | 126 | BB 1101 Dexamethasone Dexamethasone 2… Dexamethasone a… Flurbiprofen Flurbiprofen ax… Carcinoma, Non-… Dexamethasone Flubiprofen Axe… Long-term Effec… Surgery | Protocol violation occurred frequently during the postoperative period. - | |||
| NCT00063934 Details | 2019-03-05 Interventional | 1/2 | 31 | Docetaxel Doxorubicin Lenograstim Liposomal doxor… Oblimersen Breast Neoplasm… Breast Neoplasm… Male Breast Can… Stage IIIA Brea… Stage IIIB Brea… Stage IIIC Brea… Stage IV Breast… | - - | |||
| NCT02846792 Details | 2019-03-04 Interventional | 1/2 | 5 | Nivolumab Carcinoma, Non-… Lung Neoplasms ALK Gene Transl… EGFR Activating… ROS1 Gene Trans… Recurrent Non-S… Stage IIIB Non-… Stage IV Non-Sm… | Immunotherapy approved for NSCLC in the first line setting Study terminated (stopped prematurely), due to immunotherapy approved for NSCLC in the first line setting. Participant flow, Baseline Characteristics and Adverse Events recorded for 5 patients treated on study. | |||
| NCT02109965 Details | 2019-03-04 Interventional | 4 | 12 | Dexmedetomidine Midazolam Propofol Sepsis Toxemia Severe Sepsis | - - | |||
| NCT02131155 Details | 2019-03-01 Interventional | 3 | 36 | Afatinib Head and Neck N… | - The study was early terminated by the sponsor along with the global companion trial 1200.131 (NCT01345669), following the recommendation from the external Data Monitoring Committee (DMC) due to futility of 1200.131, but not due to safety concern. | |||
| NCT01701323 Details | 2019-03-01 Interventional | 1 | 7 | Cytarabine Fludarabine Fludarabine pho… Leukemia Leukemia, Myelo… Leukemia, Myelo… Acute Leukemia … Acute Myeloid L… | - - | |||
| NCT02738905 Details | 2019-02-28 Interventional | 1 | 0 | Rifaximin Kidney Diseases Kidney Failure,… End Stage Renal… | insufficient support - | |||
| NCT02269085 Details | 2019-02-28 Interventional | 1 | 8 | Ibrutinib Lymphoma Lymphoma, Mantl… | slow accrual - | |||
| NCT01163084 Details | 2019-02-28 Interventional | 1/2 | 10 | Goserelin Leuprolide Adenocarcinoma Prostatic Neopl… Prostate Adenoc… Stage IIA Prost… Stage IIB Prost… | - - | |||
| NCT02575365 Details | 2019-02-27 Interventional | 4 | 4 | Fingolimod Hydr… Nerve Degenerat… Brain Volume Lo… Cognition | The trial was terminated due to low enrollment. The trial was terminated due to low enrollment. | |||
| NCT02444793 Details | 2019-02-27 Interventional | 1 | 24 | Mogamulizumab Neoplasms Advanced/Metast… | The study was terminated due to marginal efficacy and change in sponsor prioritization. The
combination had a manageable safety profile. The study was terminated due to marginal efficacy and change in sponsor prioritization. No participants were enrolled in the dose-expansion portion. |